Evidence map›Paper›PMID 26770453›Full record

ArticleInternational journal of clinical and experimental medicine2015

Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

Yueming Chen, Xueyan Dong, Daojun Yu, Xianjun Wang

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Overexpression of miR-96 promotes cell proliferation by targeting FOXF2 in prostate cancer.International journal of clinical and experimental pathology · 2017
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yueming ChenDepartment of Laboratory Medicine, Hangzhou First People's Hospital Hangzhou, Zhejiang, China.
Xueyan DongDepartment of Laboratory Medicine, Hangzhou First People's Hospital Hangzhou, Zhejiang, China.
Daojun YuDepartment of Laboratory Medicine, Hangzhou First People's Hospital Hangzhou, Zhejiang, China.
Xianjun WangDepartment of Laboratory Medicine, Hangzhou First People's Hospital Hangzhou, Zhejiang, China.
Hangzhou First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are involved in cancer biology, and some distinctive serum miRNAs could be useful for cancer diagnosis and prognosis. However, little is known about whether serum miR-96 is a satisfactory biomarker for hepatocellular carcinoma (HCC). Four hundreds and fourteen participants were enrolled in this study, and they were divided into four age- and gender-matched groups, including the HCC group (n = 104), liver cirrhosis (LC) group (n = 90), chronic hepatitis B (CHB) group (n = 100) and healthy control group (n = 120). Serum miR-96 was measured by real-time PCR, the levels of which were calculated by the 2(-ΔCt) method. Serum miR-96 levels in the HCC patients were remarkably higher than in the other groups (P < 0.01), and the serum miR-96 levels discriminated HCC patients from CHB patients with an area under the ROC curve (AUC) of 0.803 (77.9% sensitivity and 75.3% specificity). Furthermore, the AUC for combined miR-96 and α-fetoprotein (AFP) was 0.889 (83.6% sensitivity and 82.4% specificity). High serum miR-96 levels in HCC patients were associated with larger tumor size, higher prevalence of lymph node metastasis, higher TNM stage and worse overall survival (OS) (P < 0.05). Our findings suggest that serum miR-96 is a promising biomarker for HCC patients with chronic HBV infection.

Indexed as

biomarkerchronic hepatitis BHepatocellular carcinomaliver cirrhosismicroRNA-96

Identifiers

PMID26770453
PMCPMC4694353
OpenAlexW2409569654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.